Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Q&As & Interviews

Interview with Valentina Mosienko, Fellow and Lecturer in Neuroscience, University of Bristol

Edited by Tom Cohen | 21 March 2023
Navigating the neuroscientific pathways for anxiety towards druggable targets.
https://www.youtube.com/watch?v=12d9uG3NPBk

Visit our Discovery Portal to learn more about the latest research into drug design, development, and more. If you’d like to register your interest for Oxford Global‘s upcoming conference, Organ Modelling 2023, click here.

Get your weekly dose of industry news?here?and keep up to date with the latest?‘Industry Spotlight’ posts.?For other Discovery content, please visit the?Discovery Content Portal.

Related Resources

Cobenfy: A Critical Breakthrough in Schizophrenia Treatment in Over 30 Years

According to a recent press release, the US FDA has approved Cobenfy, a first-in-class muscarinic agonist developed by Bristol Myers Squibb for the treatment of schizophrenia in adults.
Read More

Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments

Two case studies show how digital therapeutics can potentially treat neurological and neuropsychiatric conditions, areas where conventional therapeutics have encountered obstacles.
Read More